June 14, 2021 – OraSure Technologies, Inc. (Bethlehem, PA) announced it is collaborating with the Will Rodgers Liver Health Foundation to promote testing services for HCV within the US and increase awareness around the role Hepatitis C (HCV) plays in chronic liver disease.
Inspired by Will Rodgers’ personal endurance with liver disease, the Will Rodgers Liver Health Foundation was formed in 2020 to fill gaps for those affected with liver health issues by providing education, testing resources, and a link to care. The Will Rodgers Liver Health Foundation’s vision is to build awareness and provide education of liver disease, remove any barriers for treatment of liver diseases from targeted demographics, provide link-to-care in targeted communities, and eliminate the negative stigma surrounding liver disease.
The foundation’s effort, driven by Rodgers, is culminating into his overall vision — a brand new philanthropic campaign to raise awareness for HCV — RaceToEndHepC.com.
The Will Rodgers Liver Health Foundation will provide an interactive environment at race events and select community locations to encourage liver health. Through his collaboration with OraSure, individuals will be provided with free HCV testing, which provides results in minutes with a finger prick, educational materials and resources to take the next step for those with liver health needs.
“At OraSure, we take public health seriously and have played a significant role in combating diseases such as HCV, HIV, and COVID-19 on a global basis. Our OraQuick HCV rapid antibody test is designed to be extremely simple to use, highly accurate and provides a result within 20 minutes, while simultaneously being cost effective,” said OraSure President and CEO Stephen Tang, Ph.D. “As a company, we are extremely proud to collaborate with the Will Rodgers Liver Health Foundation to drive greater awareness around the importance of individuals knowing their HCV status. A simple test can save a life.”